Report unexplained muscle symptoms.
Muscle pain, tenderness or weakness, especially with fever or malaise, warrants prompt assessment for myopathy/rhabdomyolysis. Combination therapies add their own risks.
Warnings and precautionsIndications
Labeled lipid and sterol disorders.
Labeled uses
| Population / disease | Labeled use as adjunct to diet |
|---|---|
| Adults · primary hyperlipidemia, including HeFH | Reduce LDL-C with a statin, or alone when additional LDL-C-lowering therapy is not possible. |
| Age ≥10 · HeFH | Reduce LDL-C in combination with a statin. |
| Adults · mixed hyperlipidemia | Reduce LDL-C in combination with fenofibrate. |
| Adults and age ≥10 · HoFH | Reduce LDL-C with a statin and other LDL-C-lowering therapies. |
| Adults and age ≥9 · homozygous familial sitosterolemia | Reduce elevated sitosterol and campesterol. |
Dosage and administration
One daily tablet with product-specific combination review.
Labeled oral regimen
10 mg once daily with or without food. Take at least 2 hours before or 4 hours after a bile acid sequestrant such as cholestyramine. If missed, take as soon as possible; do not double the next dose. Assess LDL-C when clinically appropriate, as early as 4 weeks after starting.
Dose considerations
No renal adjustment is necessary. Moderate/severe hepatic impairment (Child-Pugh B/C): use is not recommended. Follow the exact statin, fenofibrate or other companion label for its doses, contraindications and organ-impairment restrictions; no universal combination regimen is supplied here.
Safety
Muscle, liver and combination-treatment risks.
Warnings and precautions
Transaminases may rise; test liver enzymes as clinically indicated and consider withdrawal if ALT/AST ≥3 times the upper limit of normal persist. Myopathy and rhabdomyolysis can occur, often with statins or fibrates; discontinue ezetimibe and other relevant medicines if myopathy is suspected. Companion lipid-lowering drugs retain their own warnings.
Contraindications
Ezetimibe or ingredient hypersensitivity, including anaphylaxis, angioedema, rash or urticaria. A combination is contraindicated when its statin, fenofibrate or other LDL-C-lowering partner is contraindicated; check that partner’s current label.
Boxed warning status
The reviewed Zetia label has no boxed warning. This does not remove liver, muscle, allergy or companion-drug risks.
Adverse reactions and overdose
Monotherapy trials report upper respiratory infections, diarrhea, arthralgia, sinusitis, extremity pain and fatigue. With statins, myalgia and nasopharyngitis are reported. Serious postmarketing reactions include pancreatitis, hepatitis, gallstones/cholecystitis and hypersensitivity. For overdose, contact Poison Help or a medical toxicologist.
Drug interactions
Sequestrant timing, cyclosporine exposure and gallstones.
Clinically relevant interactions
- Cholestyramine reduces total ezetimibe exposure: give ezetimibe ≥2 hours before or ≥4 hours after bile acid sequestrants.
- Cyclosporine raises ezetimibe and cyclosporine concentrations; monitor cyclosporine levels and weigh exposure risk, especially with severe renal insufficiency.
- Fenofibrate and ezetimibe can increase biliary cholesterol and gallstones. If suspected, obtain gallbladder studies and consider an alternative lipid plan.
- Fibrates other than fenofibrate are not recommended with Zetia. Statins/fibrates can add muscle and liver risks.
Use in specific populations
Pregnancy, breastfeeding and disease-specific ages.
Pregnancy and lactation
Human pregnancy data are insufficient; use only when potential benefit justifies fetal risk. Review the companion statin’s current pregnancy guidance separately. Human-milk and infant-effect data are unavailable; the label advises against nursing use unless benefit justifies infant risk. Discuss pregnancy or feeding plans with the treating clinician.
Pediatric, geriatric and organ impairment
HeFH/HoFH combination indications begin at age 10; homozygous sitosterolemia at 9. Other pediatric lipid disorders and younger ages are not established. No overall geriatric safety/effectiveness difference was observed. No renal dose adjustment; moderate/severe hepatic impairment is not recommended because increased exposure has uncertain effects.
Clinical pharmacology
NPC1L1 inhibition reduces intestinal sterol uptake.
Mechanism and pharmacokinetics
Ezetimibe targets intestinal NPC1L1 at the brush border, reducing cholesterol/phytosterol absorption, hepatic cholesterol stores and increasing LDL-receptor clearance from blood. It is extensively glucuronidated in intestine/liver to an active metabolite; enterohepatic recycling contributes to exposure. Elimination is primarily fecal, with some urinary recovery.
- Half-life
- About 22 hours for ezetimibe and its active glucuronide.
- Protein binding
- Greater than 90% for both.
- Food / metabolism
- Food does not change extent of absorption; minimal oxidative metabolism.
Monitoring and counseling
Measure lipid response and assess muscle/liver symptoms.
Monitoring parameters
- Assess LDL-C when appropriate, as early as 4 weeks after initiation; sterol response follows the specific sitosterolemia plan.
- Check liver enzymes as clinically indicated; persistent ≥3×ULN elevations may warrant withdrawal.
- Assess unexplained muscle symptoms for myopathy; CK testing is part of suspected myopathy assessment, not a universal scheduled test.
- Monitor cyclosporine concentrations and gallbladder symptoms when relevant; apply companion-drug monitoring.
Patient counseling information
Continue the prescribed diet and exact medication plan. Report muscle pain/weakness, fever, severe allergy or liver symptoms promptly. Separate cholestyramine and similar drugs by the stated interval. Do not double a missed dose. Disclose new prescriptions, supplements, pregnancy or breastfeeding.
Product identification
Selected Organon oral tablet.
Representative product · Zetia 10 mg tablet
- Appearance / imprint
- White to off-white, capsule-shaped; 414 on one side.
- Manufacturer / distributor
- Organon LLC.
- Example NDC
- 78206-178-01 · bottle of 30.
- U.S. status
- Prescription.
Dosage forms and strengths
- Selected form
- 10 mg oral tablet.
- Outside scope
- Fixed statin/ezetimibe or other combination products, other manufacturers and compounded forms; verify separate labeling.
Storage and handling
Store at 20–25°C and protect from moisture. Check exact inactive ingredients if an excipient allergy is suspected.
References
Original sources for the clinical and product information.
- DailyMed / official U.S. product labelingZetia · Full prescribing information
Clinical PI revision July 2023; document footer uspi-og0653-t-2402r003. SPL v8/effective November 25, 2025; DailyMed API publication November 26, 2025. Checked October 1, 2026.